Yardley, Pennsylvania, United States, November 20, 2026
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has announced that the U.S. Food and Drug Administration (FDA) will not take action on its Biologics License Application (BLA) for molgramostim inhalation solution by the previously established November 22, 2026 Prescription Drug User Fee Act (PDUFA) target date. The application is seeking approval of molgramostim for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare and potentially serious lung disease. According to Savara, the FDA has confirmed that its review remains ongoing but has not provided a revised action date. The development represents a delay in the regulatory process for the investigational treatment, which had previously received Priority Review status. Savara stated that it appreciates the agency’s continued work on the application and looks forward to collaborating with the FDA to complete the review. The announcement does not indicate that the application has been rejected or that the FDA has issued a Complete Response Letter. Instead, the regulatory assessment remains active, leaving the timing of a final decision uncertain. The outcome is important for patients affected by autoimmune PAP, who have limited treatment options, and for the company’s efforts to bring a targeted respiratory therapy to this underserved population.
FDA Review of Molgramostim Application Remains Ongoing
The molgramostim BLA was submitted to the FDA for the treatment of adults with autoimmune PAP. The agency previously accepted the application for review under its Priority Review programme, initially establishing an August 22, 2026 target action date. In April 2026, the FDA extended the review period by three months, moving the PDUFA date to November 22, 2026. Savara explained at that time that responses to additional FDA information requests constituted a major amendment to the application, resulting in the extension. The company reported that the agency had not identified safety, efficacy or manufacturing concerns in its correspondence regarding that extension. The latest announcement confirms that the FDA will not complete its review by the revised November deadline. However, the company has not disclosed a new target date or provided further details about the reason for the latest delay. A PDUFA date is a target for regulatory action rather than a guaranteed approval date. The FDA may require additional time to assess clinical, manufacturing or other regulatory information before reaching a decision. Until the agency completes its review, molgramostim remains investigational and cannot be described as an FDA-approved treatment for autoimmune PAP.
Molgramostim Targets the Underlying Disease Mechanism
Molgramostim is an investigational recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) designed to address the underlying biological dysfunction associated with autoimmune PAP. In healthy lungs, specialised immune cells known as alveolar macrophages help remove excess surfactant, a mixture of proteins and lipids that lines the air sacs and supports normal lung function. These macrophages depend on GM-CSF signalling to perform their surfactant-clearance function. In autoimmune PAP, the immune system produces antibodies that neutralise GM-CSF, preventing alveolar macrophages from functioning effectively. Consequently, surfactant accumulates in the alveoli, interfering with the exchange of oxygen and carbon dioxide. Molgramostim is designed to replace the deficient GM-CSF activity and help restore the macrophages’ ability to clear accumulated surfactant. The medicine is administered through inhalation using an investigational eFlow Nebulizer System developed by PARI Pharma GmbH, which was specifically designed for delivering molgramostim. This inhaled approach aims to deliver the therapeutic protein directly to the lungs. The medicine’s safety and efficacy have not yet been established through regulatory approval, and further FDA assessment is required before it can become commercially available for this indication.
Rare Respiratory Disease Highlights Unmet Medical Need
Autoimmune PAP is a rare lung disorder characterised by the progressive accumulation of surfactant within the alveoli. Patients may experience shortness of breath, persistent cough and fatigue, while some can develop more serious respiratory complications. Impaired gas exchange can significantly affect daily activities and quality of life. In advanced cases, the disease may be associated with pulmonary fibrosis, secondary infections and the potential need for lung transplantation. Existing management approaches include whole-lung lavage, a procedure in which the lungs are washed under general anaesthesia to remove accumulated material. Although this intervention can provide clinical benefit, it is invasive and may require repeated treatment. Molgramostim is being developed as a potential pharmacological alternative that addresses the disease mechanism through GM-CSF replacement. The FDA’s ongoing review will determine whether the available clinical and manufacturing evidence is sufficient to support approval. For Savara, completing the regulatory process remains a significant milestone in its rare respiratory disease development programme. For patients and healthcare professionals, the timing and outcome of the review remain important because of the limited treatment options currently available. No revised FDA action date has been announced, and the company has not confirmed when a final regulatory decision will be made.
Source: Savara Inc. press release



